New & Notable
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.
— BioPharma Dive
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency’s new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.
— PharmaVoice
Novo hikes guidance on Wegovy pill’s fast sales start
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
— BioPharma Dive
Deloitte warns of a "bubble effect" caused by the GLP-1 boom
GLP-1 therapies have helped boost Big Pharma's R&D returns for the third year in a row, but Deloitte warns that the industry's focus on these treatments is fueling a "bubble effect."
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
OpenAI debuts AI model GPT-Rosalind to speed up drug discovery
Biopharma companies, including Moderna and Amgen, are working with OpenAI to integrate its new artificial intelligence model into their workflows to accelerate research and discovery.
-
AWS launches AI-driven tool to speed up early-stage antibody discovery
Amazon Web Services launches Amazon Bio Discovery, an AI-powered drug discovery tool to help speed up the development of antibody therapies.
-
FDA reminds sponsors, researchers to report clinical trial results
As part of its ongoing push for greater transparency, the FDA is seeking voluntary compliance from thousands of clinical trial sponsors and investigators, reminding them to publicly publish findings within one year of trial completion.
-
Amazon Pharmacy adds Lilly's obesity pill with same-day delivery
Amazon's pharmacy now sells Eli Lilly's recently approved weight loss pill at in-office kiosks and offers same-day delivery online.
-
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform
With the addition of AbbVie and Genentech this week, the number of Big Pharma companies now offering certain branded medications on TrumpRx has grown to 11.
-
Drug manufacturing deals move to Europe despite pharma tariffs
Last year marked the sharpest decline in U.S. contract manufacturing deals for FDA-approved drugs in half a decade, despite Trump's push for domestic onshoring, GlobalData finds.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.